Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Neurooncol

Search In Journal Title:

Abbravation: Journal of Neuro-Oncology

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1007/978-3-662-48768-6_78

Search In DOI:

ISSN

1573-7373

Search In ISSN:
Search In Title Of Papers:

The efficacy and safety of various dosedense regi

Authors: Wei Wei Xin Chen Ximeng Ma Dawei Wang Zongze Guo
Publish Date: 2015/09/03
Volume: 125, Issue: 2, Pages: 339-349
PDF Link

Abstract

The goal of this metaanalysis was to identify the temozolomide TMZ regimen with optimal efficacy and tolerance for treatment of recurrent highgrade glioma HGG The PubMed and EMBASE databases were searched from the earliest records to February 2015 which identified 33 studies with 1760 participants that met the inclusion criteria The standard schedule and three most common dosedense regimens of TMZ therapy for recurrent HGG were included in this metaanalysis The schedule of 7 days on/7 days off for the treatment of grade IV gliomas was significantly superior to the standard regimen with respect to progressionfree survival at 6 months 348  95  confidence interval CI 270–434  and 12 months 155  95  CI 107–218  For grade III gliomas this regimen conveyed a significantly greater overall survival OS rate at 12 months 790  95  CI 562–917  as compared to the standard schedule Also the 21 days on/7 days off regimen had significantly longer OS rates at 6 months 736  95  CI 634–818  and 12 months 406  95  CI 326–486  than the standard regimen for grade IV gliomas In addition the standard schedule showed a significantly higher clinical benefit rate than the 7 days on/7 days off and 21 days on/7 days off regimens However the grade 3–4 toxicity rate of lymphopenia of the standard schedule was 765  95  CI 455–927  which was the highest among the four regimens Recurrent HGG patients receiving personalized treatment should be closely followed up especially those with concurrent hematological diseases


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma
  2. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells
  3. Origins and clinical implications of the brain tumor stem cell hypothesis
  4. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design
  5. All- trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model
  6. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
  7. Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis
  8. Phase II trial of temozolomide in children with recurrent high-grade glioma
  9. Management of patients with recurrence of diffuse low grade glioma
  10. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms
  11. Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery
  12. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types
  13. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma
  14. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
  15. A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
  16. Extraneural metastatic medulloblastoma in an adult
  17. Incidence of craniopharyngioma in Denmark ( n = 189) and estimated world incidence of craniopharyngioma in children and adults
  18. Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery
  19. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades
  20. Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas
  21. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma
  22. Multiple paraneoplastic diseases occurring in the same patient after thymomectomy
  23. Age alone is not a predictor for survival in glioblastoma
  24. Clear cell Meningioma, an uncommon variant of meningioma: a clinicopathologic study of nine cases
  25. Weight of epilepsy in brain tumor patients
  26. Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH–cortisol and renin–angiotensin–aldosterone
  27. PI3Kinase signaling in glioblastoma
  28. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
  29. Gamma Knife radiosurgery for brainstem metastases: the UCSF experience
  30. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma
  31. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03
  32. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma
  33. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults
  34. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells
  35. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors
  36. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
  37. Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery
  38. Variation of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
  39. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
  40. Rho GTPases in primary brain tumor malignancy and invasion
  41. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma
  42. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’
  43. Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma
  44. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease
  45. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
  46. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
  47. Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal
  48. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors
  49. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
  50. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas
  51. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics
  52. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma
  53. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen
  54. Images in neuro oncology: Primary extraaxial cerebellopontine angle ependymoma
  55. The peabody picture vocabulary test as a pre-screening tool for global cognitive functioning in childhood brain tumor survivors
  56. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma
  57. Skull base meningiomas: neurological outcome after microsurgical resection
  58. Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center
  59. Caloric restriction reduces edema and prolongs survival in a mouse glioma model
  60. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study
  61. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

Search Result: